Correlation Between Aquestive Therapeutics and Estrella Immunopharma

Can any of the company-specific risk be diversified away by investing in both Aquestive Therapeutics and Estrella Immunopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aquestive Therapeutics and Estrella Immunopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aquestive Therapeutics and Estrella Immunopharma, you can compare the effects of market volatilities on Aquestive Therapeutics and Estrella Immunopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aquestive Therapeutics with a short position of Estrella Immunopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aquestive Therapeutics and Estrella Immunopharma.

Diversification Opportunities for Aquestive Therapeutics and Estrella Immunopharma

-0.66

Correlation Coefficient

Aquestive Therapeutics  Estrella Immunopharma

Excellent diversification

The 3 months correlation between Aquestive and Estrella is -0.66. Overlapping area represents the amount of risk that can be diversified away by holding Aquestive Therapeutics and Estrella Immunopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Estrella Immunopharma and Aquestive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aquestive Therapeutics are associated (or correlated) with Estrella Immunopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Estrella Immunopharma has no effect on the direction of Aquestive Therapeutics i.e., Aquestive Therapeutics and Estrella Immunopharma go up and down completely randomly.

Pair Corralation between Aquestive Therapeutics and Estrella Immunopharma

Given the investment horizon of 90 days Aquestive Therapeutics is expected to generate 0.44 times more return on investment than Estrella Immunopharma. However, Aquestive Therapeutics is 2.3 times less risky than Estrella Immunopharma. It trades about 0.08 of its potential returns per unit of risk. Estrella Immunopharma is currently generating about 0.01 per unit of risk. If you would invest  86.00  in Aquestive Therapeutics on September 15, 2024 and sell it today you would earn a total of  275.00  from holding Aquestive Therapeutics or generate 319.77% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Aquestive Therapeutics  vs.  Estrella Immunopharma

Aquestive Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aquestive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Estrella Immunopharma

Risk-Adjusted Performance

6 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Estrella Immunopharma are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent essential indicators, Estrella Immunopharma sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Aquestive Therapeutics and Estrella Immunopharma

The main advantage of trading using opposite Aquestive Therapeutics and Estrella Immunopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aquestive Therapeutics position performs unexpectedly, Estrella Immunopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Estrella Immunopharma will offset losses from the drop in Estrella Immunopharma's long position.

The idea behind Aquestive Therapeutics and Estrella Immunopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..